title: Amplification of c-erbB-2, int-2 and c-myc genes in node-negative breast carcinomas. Relationship to prognosis.
abstract: Primary tumours from 100 Norwegian node-negative breast carcinoma patients were examined for c-erbB-2, int-2, and c-myc proto-oncogene amplification. c-erbB-2, int-2, and c-myc amplification was found in 12.1% (12 of 99), 8.6% (8 of 93), and 1.1% (1 of 89) of the samples respectively. All the c-erbB-2 amplified tumours were of the ductal type, and all the int-2 amplified tumours were oestrogen receptor positive. No other significant or borderline significant associations between gene amplification and clinical or histopathological parameters were found. Relapse occurred more frequently in patients with c-erbB-2 gene amplification (relapse in 33.3% of the patients with c-erbB-2 amplification compared to 20.7% in the non-amplified group), but the difference was not statistically significant, int-2 amplification was not associated with increased risk of relapse, whereas the prognostic value of the c-myc amplification could not be evaluated.
authors.affiliation: Department of Medical Oncology, Norwegian Radium Hospital, Oslo.
authors.forename: L
authors.initials: L
authors.lastname: Ottestad
authors.forename: T I
authors.initials: TI
authors.lastname: Andersen
authors.forename: J M
authors.initials: JM
authors.lastname: Nesland
authors.forename: M
authors.initials: M
authors.lastname: Skrede
authors.forename: K M
authors.initials: KM
authors.lastname: Tveit
authors.forename: K
authors.initials: K
authors.lastname: Nustad
authors.forename: A L
authors.initials: AL
authors.lastname: Børresen
mesh_terms: D000328:Adult; D001943:Breast Neoplasms / Q000235:genetics* / Q000401:mortality* / Q000473:pathology; D002277:Carcinoma / Q000235:genetics* / Q000401:mortality* / Q000473:pathology / Q000556:secondary; D051518:Fibroblast Growth Factor 3; D005346:Fibroblast Growth Factors / Q000032:analysis*; D005784:Gene Amplification; D015870:Gene Expression; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000235:genetics* / Q000401:mortality; D009664:Norway; D011379:Prognosis; D000090063:Proto-Oncogene Mas; D011518:Proto-Oncogene Proteins / Q000032:analysis*; D016271:Proto-Oncogene Proteins c-myc / Q000032:analysis*; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D016019:Survival Analysis
chemical_list: D051518:Fibroblast Growth Factor 3; D005346:Fibroblast Growth Factors; D000090063:Proto-Oncogene Mas; D011518:Proto-Oncogene Proteins; D016271:Proto-Oncogene Proteins c-myc; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; C496444:FGF3 protein, human; C000715470:MAS1 protein, human